Estrogen receptor signaling is reprogrammed during breast tumorigenesis

Significance Abnormal estrogen receptor (ER) signaling drives the majority of breast cancers and is targeted by endocrine therapies. However, in normal breast tissue, ER signaling has been demonstrated to promote benign functions such as development and differentiation. Using genomic techniques to characterize ER function in normal breast and breast tumors, this study reveals differential patterns of ER signaling, suggesting that normal ER signaling is lost and tumorigenic ER signaling gained during breast tumor formation. Better understanding of this process can aid the development of improved breast cancer prevention strategies and therapies. Limited knowledge of the changes in estrogen receptor (ER) signaling during the transformation of the normal mammary gland to breast cancer hinders the development of effective prevention and treatment strategies. Differences in estrogen signaling between normal human primary breast epithelial cells and primary breast tumors obtained immediately following surgical excision were explored. Transcriptional profiling of normal ER+ mature luminal mammary epithelial cells and ER+ breast tumors revealed significant difference in the response to estrogen stimulation. Consistent with these differences in gene expression, the normal and tumor ER cistromes were distinct and sufficient to segregate normal breast tissues from breast tumors. The selective enrichment of the DNA binding motif GRHL2 in the breast cancer-specific ER cistrome suggests that it may play a role in the differential function of ER in breast cancer. Depletion of GRHL2 resulted in altered ER binding and differential transcriptional responses to estrogen stimulation. Furthermore, GRHL2 was demonstrated to be essential for estrogen-stimulated proliferation of ER+ breast cancer cells. DLC1 was also identified as an estrogen-induced tumor suppressor in the normal mammary gland with decreased expression in breast cancer. In clinical cohorts, loss of DLC1 and gain of GRHL2 expression are associated with ER+ breast cancer and are independently predictive for worse survival. This study suggests that normal ER signaling is lost and tumor-specific ER signaling is gained during breast tumorigenesis. Unraveling these changes in ER signaling during breast cancer progression should aid the development of more effective prevention strategies and targeted therapeutics.

[1]  Feng-hua Liu,et al.  A systematic analysis , 2020 .

[2]  M. Dowsett,et al.  Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy , 2018, Proceedings of the National Academy of Sciences.

[3]  Bo Li,et al.  VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis , 2018, BMC Bioinformatics.

[4]  Henry W. Long,et al.  Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. , 2018, Cancer cell.

[5]  Brendan J. McConkey,et al.  The GRHL2/ZEB Feedback Loop—A Key Axis in the Regulation of EMT in Breast Cancer , 2017, Journal of cellular biochemistry.

[6]  D. Lowy,et al.  DLC1: a tumor suppressor that regulates Rho signaling , 2017, Oncotarget.

[7]  Tao Liu,et al.  ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline , 2016, BMC Bioinformatics.

[8]  Shenglin Mei,et al.  Modeling cis-regulation with a compendium of genome-wide histone H3K27ac profiles , 2016, Genome research.

[9]  G. Raj,et al.  Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer , 2016, Science Advances.

[10]  D. Lowy,et al.  DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers , 2016, Oncotarget.

[11]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[12]  R. Dillon,et al.  The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity , 2015, BMC Cancer.

[13]  Scott D. Findlay,et al.  Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles , 2015, Breast Cancer Research.

[14]  B. Karlan,et al.  Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells , 2015, PloS one.

[15]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[16]  Melissa A. Troester,et al.  Benign Breast Tissue Composition in Breast Cancer Patients: Association with Risk Factors, Clinical Variables, and Gene Expression , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[17]  James X. Sun,et al.  Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer , 2014, Clinical Cancer Research.

[18]  H. Ford,et al.  Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. , 2013, Cancer research.

[19]  Udo Schumacher,et al.  Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer* , 2013, The Journal of Biological Chemistry.

[20]  I. Ng,et al.  EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers , 2013, PloS one.

[21]  R. Schiff,et al.  PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. , 2013, Cancer cell.

[22]  Min Chen,et al.  Dynamic functions of RhoA in tumor cell migration and invasion , 2013, Small GTPases.

[23]  F. Bi,et al.  Role of Activated Rac1/Cdc42 in Mediating Endothelial Cell Proliferation and Tumor Angiogenesis in Breast Cancer , 2013, PloS one.

[24]  Y. Shang,et al.  Estrogen and cancer. , 2013, Annual review of physiology.

[25]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[26]  Hong Jiang,et al.  Grhl2 Determines the Epithelial Phenotype of Breast Cancers and Promotes Tumor Progression , 2012, PloS one.

[27]  Yong Zhang,et al.  Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[29]  B. Cieply,et al.  Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. , 2012, Cancer research.

[30]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[31]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[32]  Alan D. Lopez,et al.  Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis , 2011, The Lancet.

[33]  David P. Davis,et al.  A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis , 2011, Proceedings of the National Academy of Sciences.

[34]  J. Carroll,et al.  FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response , 2010, Nature Genetics.

[35]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[36]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[37]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[38]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[39]  A. Howell.  The endocrine prevention of breast cancer. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[40]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[41]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[42]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[43]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[44]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[45]  S. Goodison,et al.  The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. , 2005, Cancer research.

[46]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[47]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[48]  V. Jordan,et al.  The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  S. Thorgeirsson,et al.  DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity , 2003, Oncogene.

[50]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.